abstracts: https://doi.org/10.1182/blood-2018-152
This data as json
| doi | article_title | article_date | session_type | topics | author_names | author_affiliations | first_author_latitude | first_author_longitude |
|---|---|---|---|---|---|---|---|---|
| https://doi.org/10.1182/blood-2018-152 | Lyra: A Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (Cybord) in Newly Diagnosed and Relapsed Patients (Pts) with Multiple Myeloma (MM) | November 29, 2018 | 653. Myeloma: Therapy, excluding Transplantation: Novel Antibody Combinations in Myeloma | ["Habte Yimer, MD", "Jason Melear, MD", "Edward Faber, DO, MS", "William Bensinger, MD", "John M Burke", "Mohit Narang, MD", "Don Stevens, MD", "Sriya W. Gunawardena, MD", "Yana Lutska, PharmD", "Keqin Qi, PhD", "Jon Ukropec, PhD", "Ming Qi, MD PhD", "Thomas Lin, MD PhD", "Robert M Rifkin, MD"] |